ACELYRIN, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.24 USD | 0.00% |
|
-15.37% | -43.16% |
| Apr. 05 | North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited | DJ |
| Mar. 28 | Acelyrin, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 419M |
|---|---|---|---|---|---|
| Net income 2024 * | -376M | Net income 2025 * | -476M | EV / Sales 2024 * | - |
| Net Debt 2024 * | 49.58M | Net cash position 2025 * | 70.8M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.13
x | P/E ratio 2025 * |
-0.95
x | Employees | 135 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on Acelyrin, Inc.
More recommendations
More press releases
| 1 week | -15.37% | ||
| Current month | -37.19% | ||
| 1 month | -36.24% | ||
| 3 months | -40.70% | ||
| 6 months | -55.56% | ||
| Current year | -43.16% |
1 week
4.18
5.13
1 month
4.187.01
Current year
4.188.89
1 year
4.1829.88
3 years
4.1829.88
5 years
4.1829.88
10 years
4.1829.88
| Managers | Title | Age | Since |
|---|---|---|---|
Shao Lee Lin
FOU | Founder | 57 | 20-07-26 |
Gil Labrucherie
DFI | Director of Finance/CFO | 52 | 22-06-30 |
Melanie Gloria
COO | Chief Operating Officer | - | 21-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Beth Seidenberg
BRD | Director/Board Member | 67 | 20-09-30 |
Clarence Machado
BRD | Director/Board Member | 60 | 21-04-30 |
Alan Colowick
BRD | Director/Board Member | 61 | 21-10-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 773 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 4.24 | 0.00% | 657,192 |
| 24-04-25 | 4.24 | -7.22% | 723,193 |
| 24-04-24 | 4.57 | -0.65% | 534,843 |
| 24-04-23 | 4.6 | -4.56% | 2,027,999 |
| 24-04-22 | 4.82 | -3.79% | 1,033,118 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
ACELYRIN, INC. is a late-stage clinical biopharma company. The Company is focused on providing treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The Company has two programs in late-stage clinical development. The Companyâs lead product candidate, izokibep, is being evaluated in multiple immunologic indications, including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis. The Company is also developing Lonigutamab for the treatment of thyroid eye disease (TED), as well as developing SLRN-517 in chronic urticaria. Izokibep is an inhibitor of anti-interleukin (IL)-17A in phase III development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of TED. SLRN-517, a fully IgG1 human monoclonal antibody designed to target a distinct epitope of c-KIT.
Calendar
2024-06-12
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.24
USD
Average target price
24.17
USD
Spread / Average Target
+469.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -43.16% | 419M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- SLRN Stock
